iBreastExam

Early Detection. For All.

an innovation from
UE LifeSciences

Over 650,000 Women Examined Worldwide

Health Equity Innovation Backed by Multiple Publications

Globally Recognized Award-Winning Technology

FDA Cleared

Global Women's HealthTech Award

THE WORLD BANK
IBRD • IDA | WORLD BANK GROUP

CES Consumer Technology Association

IFC International Finance Corporation
WORLD BANK GROUP

2021 Thought Leader

ACOG TV

iBreastExam™
early detection. for all

Ultra Portable Hand-held Breast Exam.
Radiation-Free. Operable by Primary Care Providers with Minimal Training. Wireless. Battery Powered. Cloud Connected. PoC with **Instant Results.**

25,000+ Women enrolled across 8 independent, international investigator-initiated publications

Sensitivity 86%*
Specificity 91%*
NPV 98%*

*Data Presented at 2019 San Antonio Breast Cancer Symposium

Affordable, earlier stage detection with minimal training

Easy — Complex
User Proficiency Level
S = Screening Tool
D = Diagnostic Tool

Stage of detection

Self Breast Exam — S

Clinical Breast Exam — S

Breast Ultrasound — D

Film Mammography — S D

Digital Mammography — S D

3D Mammo — S D

Breast MRI — D

Not adoptable for Screening in Developing Countries

Total Cost of Ownership (Equipment, Maintenance, Manpower)

Clinical Workflow

iBreastExam / CBE
Ex: 1,000 Women

→

Targeted USG/MMG
5% positive (50 Women)

→

FNA/Biopsy
0.5% positive (5 women)

Clinical Validation

Clinical Study Title, Publication	Sensitivity	Specificity	NPV	Benchmarked By
Study of Accuracy of iBreastExam as a Screening Modality to Detect Breast Lumps, **IJCIR**	88%	94%	95%	MMG,CBE
Non-invasive and low-cost technique for early detection of clinically relevant breast lesions, **Ann.Oncol.**	84%	94%	98%	MMG,USG
Clinical efficacy evaluation of a novel palpation imaging device for early detection of breast cancer in the developing world, **SABCS**	86%	91%	98%	MMG,USG
A cost-effective handheld breast scanner for use in low-resource environments, **WJSO**	86%	89%	96%	MMG,USG
Breast Tumor Detection using Piezoelectric Fingers: First Clinical Report, **J Am Coll**	83%	88%	75%	MMG
Diagnostic accuracy of a novel palpation device toimprove early detection of breast cancer in low resource settings, **SABCS**	74%	88%	N/A	MMG,USG
Clinical Utility of a Hand-Held Scanner for Breast Cancer Early Detection and Patient Triage, **JCO (ASCO)**	N/A	80%	94%	MMG,CBE
The iBreastExam versus clinical breast examination for breast evaluation in high risk and symptomatic Nigerian women, **Lancet Global Health**	86%	50%	98%	MMG,USG,CBE

iBE Connect App reports stiff breast lesions in real-time, at PoC

648 Dynamic Co-Planar Capacitive (DCPC) sensors measure tissue elasticity 20 times per second

2 Million+ scans
supplied in 12 countries

iBreastExam
Global Dashboard™

Secure, versatile and feature-rich
cloud-based repository of every scan

The New York Times

BBC WORLD NEWS

TED

Forbes Asia

Lyfebulb-Helsinn
Oncology Innovation
Award 2019

Best Pitch Innov8
Talks Arab Health
Award 2019

Bayer Foundation
Grants 4 Impact
Award 2018

+1.267.225.0453 (US Office) | **+91.22.26102610** (India Office) | **+60.3.62063079** (Malaysia Office)

info@uelifesciences.com   iBreastExam.com   facebook.com/ibreastexam